The Radiation Linear Accelerator Shared Service (RLASS) is a resource for supporting radiation studies for investigators at the University of Maryland School of Medicine, including the Mariene and Stewart Greenebaum Cancer Center (UMGCC). The shared service currently operates a state-of-the-art research megavoltage linear accelerator (Varian Medical Systems, Palo Alto, CA) that is capable of delivering photon (6-18 MV) and electron (6-18 MeV) radiation beams. This linear accelerator is equipped with state-of-the-art, onboard imaging capabilities that aid in accurate localization of radiation targets. With this combination of technologies, RLASS can replicate sophisticated treatment modalities that are offered as standard of care to patients undergoing radiation therapy. RLASS is a unique resource because most linear accelerators are typically utilized on a full-time basis for clinical radiation therapy treatments. RLASS offers cell culture irradiation, total and hemi-body irradiation, organ- and tissue-specific irradiation in the form of 3D conformal radiation therapy and intensity-modulated radiation therapy, treatment planning and 3D dose calculation capabilities, and onboard imaging. Highly skilled faculty and staff provide investigators at UMGCC with the expertise to design animal protocols and perform dosimetry calculations and measurements to ensure highly reliable estimates of whole-body, partial-body, and organ-specific doses. The effectiveness of this shared service can be gauged from the fact that it has supported the development of advanced radiation delivery and organ-motion management technologies. In addition, it has supported the development of complex nonhuman primate models of radiation-induced injury.
The availability of the Radiation Linear Accelerator Shared Service is essential to advancing technical developments at UMGCC that will spur the creation of novel treatment radiation delivery methods. The radiation linear accelerator also provides a platform to evaluate models of intervention to prevent radiation injury.
|Appelt, Ane L; Vogelius, Ivan R; Pløen, John et al. (2014) Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys 90:110-8|
|Vogelius, Ivan R; Bentzen, Søren M (2014) Hypofractionated radiation therapy for prostate cancer: more food for thought from recent trial. J Clin Oncol 32:1852-3|
|Bao, Ting; Cai, Ling; Snyder, Claire et al. (2014) Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer 120:381-9|
|Barnett, Gillian C; Thompson, Deborah; Fachal, Laura et al. (2014) A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol 111:178-85|
|Bentzen, S M; Yarnold, J (2014) A toast to the silver anniversary of Clinical Oncology: a quarter of a century of advances in evidence-based radiation dose fractionation. Clin Oncol (R Coll Radiol) 26:599-601|
|Håkansson, Katrin; Specht, Lena; Aznar, Marianne C et al. (2014) Prescribing and evaluating target dose in dose-painting treatment plans. Acta Oncol 53:1251-6|
|Due, Anne K; Vogelius, Ivan R; Aznar, Marianne C et al. (2014) Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol 111:360-5|
|Song, Xiaomeng; Xia, Ronghui; Li, Jiang et al. (2014) Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma. Clin Cancer Res 20:701-10|
|Gojo, Ivana; Tan, Ming; Fang, Hong-Bin et al. (2013) Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res 19:1838-51|
|Natarajan, Karthika; Xie, Yingqiu; Burcu, Mehmet et al. (2013) Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One 8:e74653|
Showing the most recent 10 out of 18 publications